Our team had a great time at last week’s WORLDSymposium, where we presented new data from our FLT201 gene therapy program for #Gaucher disease during oral and poster sessions. You can find highlights from Spur's WORLD presentations at our website: bit.ly/3V4lHRM

At Spur, we are principled – our team does what’s right, not what’s easy. We lead with a deep sense of responsibility to each other, and to the patient communities we aim to serve by developing gene therapies that could change the course of disease. bit.ly/3BWky8K

In an interview with CGTLive®, Dr. Reena Sharma discusses new data on FLT201, Spur’s gene therapy candidate for #Gaucher disease. Dr. Sharma shares how FLT201 leverages GCase85, designed by our scientists to be longer-acting than the natural GCase enzyme: bit.ly/4i17RsK

In Scrip, Citeline Commercial’s annual series highlighting the year’s anticipated #biotech trends, our CEO Michael Parini was featured sharing his thoughts on how Spur’s work to unlock the full potential of #genetherapy could propel the field forward in 2025: bit.ly/4k6zwKv

The symptoms of Gaucher disease can have a tremendous impact on patients’ daily lives. There are therapies available, but many people receiving these treatments still live with unaddressed symptoms. Learn how Spur is working to change that: bit.ly/3WbVQbs

At #JPM25, our CEO Michael Parini met with Precision AQ to discuss our work in #GCase-mediated conditions like #Gaucher disease and #GBA1 Parkinson’s disease. Watch the interview to learn more about our clinical and pre-clinical #genetherapy programs. bit.ly/3Db67hC

#RareDiseaseDay recognizes the impact that rare diseases have on more than 300M people worldwide. Spur is committed to pursuing an improved standard of care for rare diseases like #Gaucher disease, which affects tens of thousands of people globally. bit.ly/42ItFEK

#ICYMI: CGTLive® interviewed Dr. Reena Sharma, an investigator in the Phase 1/2 GALILEO-1 trial, to discuss our new clinical data on FLT201 in Gaucher disease. You can read Dr. Sharma’s thoughts on the “promising” data shared from the study thus far here: bit.ly/41znjGP

Spur creates gene therapy candidates with a focus on optimizing every component – we select capsids and engineer proteins to create therapies with the potential for improved safety and efficacy. Learn about our tailored approach to gene therapy: bit.ly/3PYYMoc

Our scientists rationally engineered GCase85, a version of the naturally occurring GCase enzyme, for improved stability. We are leveraging GCase85 in multiple gene therapy candidates for the treatment of Gaucher disease and Parkinson's disease. Learn more: bit.ly/4kkfcFG

Dr. Reena Sharma, an investigator in our Phase 1/2 GALILEO-1 clinical trial of FLT201, was recently interviewed by CheckRare. Highlighting positive study data, she encourages physicians treating #Gaucher patients to explore new treatment opportunities. bit.ly/4icyprk

At Spur, we are united in our commitment to patients and to each other. We work as one team, using our diverse skills and perspectives to advance our singular mission – to redefine what gene therapy can do. Visit our website to learn more about our values: bit.ly/3BWky8K

This week, our team gathered at Spur’s UK office for a tea tasting event – we got to sample some delicious tea blends, and learned about the process of making the perfect cup. We’re proud to be part of a team with a strong culture and a commitment to working #TowardMore together!

April is Parkinson’s Disease Awareness Month. There is no disease-modifying treatment available for PD, which causes symptoms like tremors and difficulty moving, as well as anxiety, depression, and cognitive impairments. Learn more at Parkinson's Foundation: bit.ly/3XzpWWY

On April 9 at 7pm ET, @Gaucher Alliance will host a webinar on the clinical development of FLT201, Spur's gene therapy candidate for the treatment of #Gaucher disease. Register to hear the latest on our ongoing clinical trial and Phase 3 plans for FLT201. bit.ly/4cnfRCr

April 11 is #WorldParkinsonsDay. Of the ~10 million people who live with Parkinson's, 5-15% have #GBA1 mutations that can lead to a more severe form of the disease. Learn more about SPR301, our novel gene therapy candidate for this patient population: bit.ly/4jbiNoe

Gaucher disease causes toxic buildup of GB-1 and lyso-Gb1 in a variety of tissues and organs, including the liver, spleen, bone, and lungs. FLT201 is a gene therapy candidate designed to clear this toxic buildup and provide a new standard of care: bit.ly/3WbVQbs

GBA1 mutations are the most common genetic risk factor for Parkinson’s disease. Learn more about our work to advance SPR301, a novel gene therapy candidate, as a potential treatment for the hundreds of thousands of people with GBA1-PD: bit.ly/42hT6gg

Spur will share three oral and poster presentations at #ASGCT2025 in New Orleans. These include an oral presentation on the durability of FLT201, our lead gene therapy candidate for the treatment of #Gaucher disease, on May 15 at 9am CT. Learn more: bit.ly/4iBGMfe

As Parkinson's Disease Awareness Month comes to an end, we're re-sharing the Cell & Gene guest column on the genetic link between Gaucher disease and Parkinson's disease authored by our CSO Henning Stennicke. Learn more about our work in these conditions: bit.ly/4aDhFXa